Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

The Invesco Biotechnology & Genome ETF (PBE), a passively managed fund with $216.8 million in assets and a 0.58% expense ratio, tracks the Dynamic Biotechnology & Genome Intellidex Index, offering concentrated exposure to 32 healthcare biotech holdings. Despite a 3.68% YTD gain, it posted a 0.79% loss over the past year (as of 09/29/2025) and is deemed high-risk with a 20.75% standard deviation, carrying a Zacks Rank of 3 (Hold) compared to larger, lower-cost alternatives like IBB and XBI.

Analysis

The Invesco Biotechnology & Genome ETF (PBE) offers specialized exposure to the biotech sector through a passively managed structure that tracks a 'smart beta' index, the Dynamic Biotechnology & Genome Intellidex. This index selects companies based on criteria including momentum, quality, and value, differentiating it from traditional market-cap weighted funds. Despite this rules-based approach, PBE's profile presents a mixed picture. With $216.8 million in assets, it is an average-sized fund, but its 0.58% expense ratio is notably higher than larger, more liquid alternatives such as IBB (0.44%) and XBI (0.35%). The fund's portfolio is highly concentrated, with only 32 holdings and the top 10 constituents accounting for 46.21% of assets, which increases single-stock risk. This concentration contributes to its high-risk profile, evidenced by a three-year standard deviation of 20.75%, even though its beta of 0.79 suggests lower sensitivity to broad market movements. Performance has been lackluster, with a 0.79% decline over the past year despite a 3.68% year-to-date gain (as of 09/29/2025). The neutral Zacks ETF Rank of 3 (Hold) reflects these trade-offs between its unique factor-based strategy and its higher costs, higher specific risk, and middling performance relative to peers.

Key Decisions for Investors

• Investors seeking targeted, factor-based exposure to the biotech sector (momentum, quality, value) may consider PBE, but must be willing to accept its higher concentration risk and costs compared to broad-based biotech ETFs.
• Given the fund's 0.58% expense ratio and 20.75% standard deviation, a thorough comparison against larger, lower-cost, and more diversified alternatives like IBB and XBI is warranted before committing capital.
• With a 'Hold' rating from Zacks and mixed performance signals, the fund does not present a clear buy signal; potential investors should monitor whether its multi-factor strategy can generate outperformance to justify its risk profile and fees.